SCHEMBL4483298

SCHEMBL4483298

C1CCN(c2nsc(N3CCNCC3)n2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
HRH1 P35367 1/20 0.58
CASP1 P29466 1/20 0.50
CASP4 P49662 1/20 0.50
CASP5 P51878 1/20 0.50
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HRH4 Q9H3N8 1/20 0.41
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
MAPT P10636 1/20 0.36
HTR2C P28335 2/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482650 0.98 HRH1 (0.60) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL13817552 0.83 HRH1 (0.42) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL4474918 0.81 ALDH1A1 (0.40) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL4472198 0.79 HRH4 (0.43) USP2SMN1; SMN2TDP1HRH1ALDH1A1
SCHEMBL778188 0.77 SMN1; SMN2 (1.00) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL8542091 0.75 HRH1 (1.00) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL3150091 0.73 DPP4 (0.42) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL11460661 0.71 CHRNB2 (0.42) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL778177 0.69 USP2 (0.81) USP2SMN1; SMN2TDP1HRH1CASP1
SCHEMBL11460326 0.69 CHRNB2 (0.37) USP2SMN1; SMN2TDP1HRH1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
WO-2007005510-A1 N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-11 WO disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase FAAH, FAAH2, CNR2 USP2 27/4885SMN1; SMN2 1755/4885TDP1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.